SCHEMBL1369967

SCHEMBL1369967

CCCCC(C)CC(C)=O

nearest known ligand 0.46

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
ACE2 Q9BYF1 1/20 0.45
CA2 P00918 7/20 0.41
MAPK1 P28482 1/20 0.41
CA1 P00915 6/20 0.40
SLC15A1 P46059 1/20 0.38
FDPS P14324 1/20 0.38
GPR84 Q9NQS5 4/20 0.38
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1782208 0.93 ACE2 (0.53) ALDH1A1TDP1ACE2CA2CA1
SCHEMBL13177054 0.93 ACE2 (0.53) ALDH1A1TDP1ACE2CA2CA1
SCHEMBL17104323 0.91 ACE2 (0.57) ALDH1A1TDP1ACE2CA2CA1
SCHEMBL13480159 0.91 ACE2 (0.57) ALDH1A1TDP1ACE2CA2CA1
SCHEMBL13176543 0.91 ACE2 (0.57) ALDH1A1TDP1ACE2CA2CA1
SCHEMBL1783969 0.91 ACE2 (0.57) ALDH1A1TDP1ACE2CA2CA1
SCHEMBL12446359 0.91 ACE2 (0.57) ALDH1A1TDP1ACE2CA2CA1
SCHEMBL2637623 0.89 ACE2 (0.55) ALDH1A1TDP1ACE2CA2CA1
SCHEMBL2637624 0.89 ACE2 (0.55) ALDH1A1TDP1ACE2CA2CA1
SCHEMBL594273 0.85

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110511721-A A kind of display fitting special-purpose organic silicon adhesive and preparation method thereof UNIV FUDAN 2019-11-29 CN claimed
US-RE46318-E1 Colored fluids for electrowetting, electrofluidic, and electrophoretic technologies SUN CHEMICAL CORPORATION (US) 2017-02-21 US claimed
US-8717663-B2 Colored fluids for electrowetting, electrofluidic, and electrophoretic technologies SUN CHEMICAL CORPORATION (US) 2014-05-06 US claimed
US-12559586-B2 Compositions containing uretdione groups crosslinking at low temperatures COVESTRO DEUTSCHLAND AG (DE) 2026-02-24 US disclosed
US-12222653-B2 Method for forming semiconductor structure TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD. (TW) 2025-02-11 US disclosed
US-20250000088-A1 ANT CONTROL AGENT AND ANT CONTROL METHOD SHIN-ETSU CHEMICAL CO., LTD. (JP) 2025-01-02 US disclosed
EP-4424164-A1 ANT CONTROL AGENT AND ANT CONTROL METHOD SHIN-ETSU CHEMICAL CO., LTD. (JP) 2024-09-04 EP disclosed
CN-118139527-A Ant control agent and ant control method 信越化学工业株式会社 2024-06-04 CN disclosed
CN-111417373-B Hair dyeing composition comprising microcapsules 弗门尼舍有限公司 2024-04-12 CN disclosed
US-20230272239-A1 LIQUID COMPOSITION, LIQUID COMPOSITION FOR INKJET DISCHARGING, DEVICE FOR MANUFACTURING LAYER CONTAINING INORGANIC OXIDE, METHOD OF MANUFACTURING LAYER CONTAINING INORGANIC OXIDE, AND ELECTROCHEMICAL DEVICE RICOH COMPANY, LTD. (JP) 2023-08-31 US disclosed
EP-4235833-A1 LIQUID COMPOSITION, LIQUID COMPOSITION FOR INKJET DISCHARGING, DEVICE FOR MANUFACTURING LAYER CONTAINING INORGANIC OXIDE, METHOD OF MANUFACTURING LAYER CONTAINING INORGANIC OXIDE, AND ELECTROCHEMICAL DEVICE Ricoh Company, Ltd. (JP) 2023-08-30 EP disclosed
US-20030008863-A1 Novel tricyclic diazepines tocolytic oxytocin receptor antagonists WYETH 2003-01-09 US disclosed
US-6476011-B1 Methods for introducing an estrogenic compound STERIX LIMITED (GB) 2002-11-05 US disclosed
CN-1376057-A Anti-virus composition JANSSEN PHARMACEUTICA NV (BE) 2002-10-23 CN disclosed
US-6307064-B1 PHENYLISOSERINE ESTER OF SILYLATED BACCATIN III PHARMACIA & UPJOHN COMPANY 2001-10-23 US disclosed
US-6214844-B1 ANTIARTHRITIC AGENTS; BONE DISORDERS; ANTIINFLAMMATORY AGENTS SMITHKLINE BEECHAM CORPORATION 2001-04-10 US disclosed
US-6075011-A 6-O-substituted erythromycin compounds and method for making same ABBOTT LABORATORIES (US) 2000-06-13 US disclosed
EP-0910567-A1 TRICYCLIC IBOGAINE ANALOGS, THEIR PREPARATION AND THEIR USE IN TREATING SUBSTANCE ABUSE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 1999-04-28 EP disclosed
WO-1997020847-A1 TRICYCLIC IBOGAINE ANALOGS, THEIR PREPARATION AND THEIR USE IN TREATING SUBSTANCE ABUSE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 1997-06-12 WO disclosed
EP-0176161-A1 Novel fluoran compounds and production and use thereof TAOKA CHEMICAL CO., LTD (JP) 1986-04-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12559586-B2 Compositions containing uretdione groups crosslinking at low temperatures URB2, UQCRB, UQCRC2 ALDH1A1 1357/4885TDP1 4236/4885ACE2 1094/4885
US-20030008863-A1 Novel tricyclic diazepines tocolytic oxytocin receptor antagonists OXTR, OPRL1, HCRTR2 ALDH1A1 3354/4885TDP1 1218/4885ACE2 1637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.